JO3638B1 - مركبات مفيدة في تثبيط ror - جاما- t - Google Patents

مركبات مفيدة في تثبيط ror - جاما- t

Info

Publication number
JO3638B1
JO3638B1 JOP/2016/0191A JOP20160191A JO3638B1 JO 3638 B1 JO3638 B1 JO 3638B1 JO P20160191 A JOP20160191 A JO P20160191A JO 3638 B1 JO3638 B1 JO 3638B1
Authority
JO
Jordan
Prior art keywords
gamma
compounds useful
inhibiting ror
ror
inhibiting
Prior art date
Application number
JOP/2016/0191A
Other languages
English (en)
Inventor
Richard Morphy John
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3638B1 publication Critical patent/JO3638B1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يوفر الاختراع الحالي مثبطات ROR جاما- t جديدة و تركيبات صيدلية منها:
JOP/2016/0191A 2015-09-09 2016-08-25 مركبات مفيدة في تثبيط ror - جاما- t JO3638B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562215929P 2015-09-09 2015-09-09

Publications (1)

Publication Number Publication Date
JO3638B1 true JO3638B1 (ar) 2020-08-27

Family

ID=56940418

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0191A JO3638B1 (ar) 2015-09-09 2016-08-25 مركبات مفيدة في تثبيط ror - جاما- t

Country Status (41)

Country Link
US (1) US9598431B1 (ar)
EP (1) EP3347360B1 (ar)
JP (1) JP6282789B1 (ar)
KR (1) KR102048780B1 (ar)
CN (1) CN108026112B (ar)
AR (1) AR105821A1 (ar)
AU (1) AU2016318593B2 (ar)
BR (1) BR112018001451B1 (ar)
CA (1) CA2994732C (ar)
CL (1) CL2018000558A1 (ar)
CO (1) CO2018002440A2 (ar)
CR (1) CR20180089A (ar)
CY (1) CY1122287T1 (ar)
DK (1) DK3347360T3 (ar)
DO (1) DOP2018000066A (ar)
EA (1) EA033882B1 (ar)
EC (1) ECSP18018793A (ar)
ES (1) ES2760992T3 (ar)
HK (1) HK1249901B (ar)
HR (1) HRP20192235T1 (ar)
HU (1) HUE047950T2 (ar)
IL (1) IL257202B (ar)
JO (1) JO3638B1 (ar)
LT (1) LT3347360T (ar)
MA (1) MA42776B1 (ar)
MD (1) MD3347360T2 (ar)
MX (1) MX2018002898A (ar)
MY (1) MY195903A (ar)
NZ (1) NZ739518A (ar)
PE (1) PE20181274A1 (ar)
PH (1) PH12018500504A1 (ar)
PL (1) PL3347360T3 (ar)
PT (1) PT3347360T (ar)
RS (1) RS59655B1 (ar)
SI (1) SI3347360T1 (ar)
SV (1) SV2018005647A (ar)
TN (1) TN2018000057A1 (ar)
TW (1) TWI597284B (ar)
UA (1) UA118824C2 (ar)
WO (1) WO2017044410A1 (ar)
ZA (1) ZA201800515B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3589638T3 (da) * 2017-03-02 2021-06-07 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-Gamma-T
SI3589637T1 (sl) * 2017-03-02 2021-08-31 Eli Lilly And Company Spojine uporabne pri inhibiciji ROR-GAMMA-T
WO2018193297A1 (en) 2017-04-21 2018-10-25 Cadila Healthcare Limited Novel compounds as ror-gamma modulators
JP2020142989A (ja) * 2017-06-21 2020-09-10 Meiji Seikaファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
US20240051969A1 (en) 2020-12-07 2024-02-15 Diaccurate Ror-gamma inhibitors for the treatment of ror-gamma-dependent cancer
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
JP3790250B2 (ja) * 2004-01-16 2006-06-28 新日鐵化学株式会社 両面導体ポリイミド積層体の連続製造方法
UA107943C2 (en) * 2009-11-16 2015-03-10 Lilly Co Eli Compounds of spiropiperidines as antagonists of the orl-1 receptors
SI2501704T1 (sl) * 2009-11-16 2013-11-29 Eli Lilly Company Spojine spiropiperidina kot antagonisti oral-1 receptorja
KR102074089B1 (ko) * 2009-12-04 2020-02-05 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
RU2014149136A (ru) * 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
KR101742954B1 (ko) * 2012-05-31 2017-06-02 페넥스 파마슈티컬스 아게 고아 핵 수용체 ror[감마]의 조절제로서의 카복사미드 또는 설폰아미드가 치환된 티아졸 및 관련된 유도체
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
US9868748B2 (en) 2013-05-01 2018-01-16 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ROR- γ
EP3027616B1 (en) 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Azaindole compounds as modulators of rorc
WO2015101928A1 (en) * 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators

Also Published As

Publication number Publication date
IL257202A (en) 2018-03-29
HK1249901B (zh) 2020-06-19
BR112018001451B1 (pt) 2023-10-10
HUE047950T2 (hu) 2020-05-28
CA2994732A1 (en) 2017-03-16
AU2016318593A1 (en) 2018-02-15
EP3347360A1 (en) 2018-07-18
MD3347360T2 (ro) 2020-03-31
JP2018507203A (ja) 2018-03-15
CR20180089A (es) 2018-02-27
MX2018002898A (es) 2018-06-18
NZ739518A (en) 2019-06-28
LT3347360T (lt) 2020-01-27
SV2018005647A (es) 2018-07-23
PT3347360T (pt) 2020-01-07
HRP20192235T1 (hr) 2020-03-20
IL257202B (en) 2020-02-27
MY195903A (en) 2023-02-27
TW201722964A (zh) 2017-07-01
CA2994732C (en) 2020-06-30
CL2018000558A1 (es) 2018-08-10
KR20180031777A (ko) 2018-03-28
AR105821A1 (es) 2017-11-15
PL3347360T3 (pl) 2020-04-30
EA033882B1 (ru) 2019-12-05
WO2017044410A1 (en) 2017-03-16
ZA201800515B (en) 2019-06-26
SI3347360T1 (sl) 2019-12-31
EA201890364A1 (ru) 2018-08-31
JP6282789B1 (ja) 2018-02-21
UA118824C2 (uk) 2019-03-11
ES2760992T3 (es) 2020-05-18
CO2018002440A2 (es) 2018-07-10
TN2018000057A1 (en) 2019-07-08
US9598431B1 (en) 2017-03-21
US20170066781A1 (en) 2017-03-09
PE20181274A1 (es) 2018-08-03
MA42776B1 (fr) 2020-02-28
CN108026112A (zh) 2018-05-11
EP3347360B1 (en) 2019-10-23
CY1122287T1 (el) 2020-11-25
AU2016318593B2 (en) 2018-10-04
TWI597284B (zh) 2017-09-01
DK3347360T3 (da) 2020-01-02
PH12018500504A1 (en) 2018-09-24
RS59655B1 (sr) 2020-01-31
CN108026112B (zh) 2020-04-10
DOP2018000066A (es) 2018-03-30
BR112018001451A2 (pt) 2018-09-11
ECSP18018793A (es) 2018-04-30
KR102048780B1 (ko) 2019-11-27

Similar Documents

Publication Publication Date Title
IL263082B (en) New compounds as ototaxin inhibitors and pharmaceutical preparations containing them
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
GEP20217239B (en) Pharmaceutical composition
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
PH12017500660A1 (en) Novel compositions, uses and methods for making them
PH12016500895A1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12018500504A1 (en) Compounds useful for inhibiting ror-gamma-t
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
MX2017013073A (es) Inhibidores de grelina o-aciltransferasa.
GEP20217240B (en) Pharmaceutical composition
MX2017013072A (es) Inhibidores de grelina o-aciltransferasa.
PH12017502028A1 (en) Vortioxetine pyroglutamate
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
AU2015311730A8 (en) CaMKII inhibitors and uses thereof
TR201620309A2 (tr) Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇